Check for updates

OPEN ACCESS

EDITED BY Ping Yang, Nanjing Agricultural University, China

REVIEWED BY Kun Li, Nanjing Agricultural University, China Tengfei Liu, Northwest A&F University, China

*CORRESPONDENCE Li Gao gaoli43450@163.com

[†]These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION This article was submitted to Comparative and Clinical Medicine, a section of the journal Frontiers in Veterinary Science

RECEIVED 01 September 2022 ACCEPTED 07 October 2022 PUBLISHED 20 October 2022

CITATION

Ma T, Chen H, Ruan H, Lv L, Yu Y, Jia L, Zhao J, Li X, Zang Y, Xu X, Zhang J and Gao L (2022) Natural product, bilobalide, improves joint health in rabbits with osteoarthritis by anti-matrix degradation and antioxidant activities. *Front. Vet. Sci.* 9:1034623. doi: 10.3389/fvets.2022.1034623

COPYRIGHT

© 2022 Ma, Chen, Ruan, Lv, Yu, Jia, Zhao, Li, Zang, Xu, Zhang and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is

reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Natural product, bilobalide, improves joint health in rabbits with osteoarthritis by anti-matrix degradation and antioxidant activities

Tianwen Ma^{1†}, Hong Chen^{1†}, Hongri Ruan^{1†}, Liangyu Lv¹, Yue Yu¹, Lina Jia¹, Jinghua Zhao², Xin Li¹, Yuxin Zang¹, Xinyu Xu¹, Jiantao Zhang^{1,3} and Li Gao^{1,3*}

¹College of Veterinary Medicine, Northeast Agricultural University, Harbin, China, ²College of Animal Science and Technology, College of Veterinary Medicine, Zhejiang Agriculture and Forestry University, Hangzhou, China, ³Heilongjiang Key Laboratory of Animals Disease Pathogenesis and Comparative Medicine, Harbin, China

Osteoarthritis (OA) is a common chronic musculoskeletal disease reported in veterinary clinics that severely reduces the quality of life of animals. The natural product, bilobalide, has positive effects on chondroprotection but its exact mechanism of action is unclear. This study aimed to investigate the antioxidant and anti-matrix degradation activities of bilobalide in a rabbit model of OA and its protective effects on joints. We also investigated the possible mechanisms underlying these effects. The rabbit OA model was established by intra-articular injection of 4% papain. Thirty healthy male New Zealand rabbits were randomly divided into control, untreated OA, Cel (100 mg/kg celecoxib intervention as a positive control), BB-L and BB-H (40 mg /kg and 80 mg /kg bilobalide gavage treatment, respectively) groups. Two weeks after surgical induction, bilobalide or celecoxib was administered by gavage daily for 8 weeks. After 8 weeks of bilobalide intervention, cartilage macroscopic observation and histopathological images showed alleviation of cartilage damage after bilobalide treatment, and the Osteoarthritis Research Society International (OARSI) score was significantly lower than that in the OA group. Bilobalide reduced the expression of metalloproteinase 3 (MMP-3) and MMP-13 in cartilage tissue of OA rabbits and reversed the levels of serum C-telopeptides of type II collagen (CTX-II), cartilage oligomeric matrix protein (COMP), interleukin 1(IL-1), and tumor necrosis factor (TNF- α). Bilobalide (80 mg/kg) could improve the biomechanical properties and microstructural changes in subchondral bone in the early stage of OA in rabbits, thereby delaying subchondral bone damage. Mechanistically, bilobalide exerted antioxidant and anti-matrix degradation effects by upregulating the oxidative stress signaling Nrf2/HO-1 pathway and inhibiting cartilage degeneration in rabbit OA. We thus speculate that bilobalide supplements recovery from OA damage.

KEYWORDS

bilobalide, Nrf2/HO-1 pathway, oxidative stress, osteoarthritis, papain

Introduction

Knee osteoarthritis (OA) is common chronic musculoskeletal disease, which can cause pain, limited mobility, and even disability (1, 2). To date, no disease-modifying therapies for OA exist due to insufficient understanding of the pathogenesis of knee OA (3). Non-steroidal anti-inflammatory drugs (NSAIDs) that, temporarily relieve pain and have no preventive or curative impact on cartilage deterioration, are among the currently available treatments for OA (4). Due to these restrictions, new, side-effect-free strategies are needed to strengthen the cartilage and stop its degeneration while enhancing overall joint health.

Bilobalide, a sesquiterpenoid derived from *Ginkgo biloba* L. extract (5), exerts anti-inflammatory (6), anti-apoptotic (7), antioxidant (8), neuroprotective (9), and microcirculationimproving properties (10). Recent research indicates that bilobalide can reduce anterior cruciate ligament transection (ACLT)-induced OA in rats through its action on chondrocytes *via* the AMPK/SIRT1/mTOR pathway to reduce inflammation (11). By inhibiting microRNA-125a, bilobalide reduces IL-17-induced inflammatory damage in the ATDC5 chondrocytes (12). Although these studies suggest that bilobalide has potential protective effects for OA, the specific mechanism remains unclear and experimental validation in animal models is lacking. Therefore, we established a rabbit OA model by injecting papain intra-articularly to observe the therapeutic impact of bilobalide, crucial for assessing its safety.

Joint inflammation and oxidative stress are directly linked to the development of OA (13–15). Upregulation of cellular antioxidant defense mechanisms in chondrocytes in several *in vitro* and *in vivo* investigations shows repression of catabolic genes expression and enhanced joint health (16–18). The master transcriptional regulator of the cellular antioxidant defense system is nuclear factor erythroid-2 related factor 2 (Nrf2). Under physiological conditions, cytoplasmic Nrf2 is sequestered by Keap1, following which it dissociates and translocates to the nucleus, where it binds to antioxidant response elements (AREs) and stimulates the transcription of HO-1 and other defense enzymes (19–21). Nrf2 activation has prevention or trerapeutic against OA. (22). Therefore, we hypothesized that the protective effect of bilobalide on papain-induced OA in rabbits was linked to the overexpression of Nrf2/HO-1.

Materials and methods

Experimental design

For the experiment, 30 adult male New Zealand white rabbits aged 3 months were chosen. The animals were acquired from the Animal Experiment Center of the Second Affiliated Hospital of the Harbin Medical University (Harbin, China), and housed in a controlled environment (light/dark, 12/12 h, and temperature 23 \pm 1°C). Each rabbit was kept in a separate cage with free access to water, and normal chow and animals were inspected daily. The rabbits were allowed to acclimatize for a week before the experimental treatment. Rabbits were randomly divided into Control (0.9% NaCl treatment, n = 6) and papain (intra-articular injection of 4% papain to induce OA model, n = 24) groups. The latter was further categorized into 4 subgroups (6 animals in each group) as follows: OA (gavage with normal saline), Cel (positive control group, administered 100 mg/kg celecoxib which was purchased from Pfizer Pharmaceuticals [New York, USA]), BB-L (administered 40 mg/kg bilobalide to treat rabbit OA), and BB-H (80 mg/kg of bilobalide was administered to treat OA in rabbits) (Figure 1). The dose selection of bilobalide was based on the results of preliminary experiment. Recent standards for best practice in natural product pharmacological research requirements that are deemed relevant were considered (23, 24). The Laboratory Animal Welfare and Ethics Committee of Northeast Agricultural University (#NEAU-2022-01-0025-1) approved the procedure for animal surgery and treatment in this study. Every attempt was made to minimize the number of animals utilized and their suffering.

Induction and treatment of OA

Chengdu Must Bio-technology Co., Ltd. (Chengdu, China) supplied the bilobalide (purity \geq 98%). OA modeling was done based on previously described protocol (25). Briefly, the rabbits in the papain group received injections of 0.1 ml 4% papain (Solarbio, China) on the first, fourth, and seventh days in the cavity of the right knee. No manipulation was performed on the left hind knee of the animal. After each intra-articular injection, the animals were allowed to walk freely in the cage. In the Cel, BB-L and BB-H groups, 7 days after the last injection of papain, the animals were administered 100 mg/kg celecoxib, 40 mg/kg bilobalide, and 80 mg/kg of bilobalide, respectively once a day for 8 weeks (Figure 1). The gavage volume of celecoxib or bilobalide for each rabbit was 3 ml. In the control group, rabbits received 0.9% NaCl by gavage. After 8 weeks of drug intervention, animals were euthanized by 20 ml/kg air embolization (30 mg/kg 3% pentobarbital sodium via ear vein) under anesthesia. The blood samples were collected, centrifuged at 1,000 \times g for 20 min, and the supernatant was collected for ELISA. Histological, western blotting, and qRT-PCR were performed on the knee cartilage.

X-ray observation of the rabbit knee joint

X-rays scans of supine rabbits were captured using a direct radiography system (Longsafe, China, Animal Clinical Teaching



Hospital of Tohoku Agricultural University). X-ray images were graded according to the Kellgren-Lawrence (KL) system (26).

Microcomputed tomography (μ CT)

On the Bruker Micro-CT Skyscan 1276 system (Kontich, Belgium), specimens were scanned. The scan settings were as follows: Voxel size, 15.067119 m; resolution, medium, and integration time, 403 ms. The calcium hydroxyapatite (CaHA) phantom provided by the manufacturer served as the standard for density measurements. The evaluation program from the manufacturer was used for the analysis. NRecon was used for the reconstruction (version 1.7.4.2). 3D images were obtained from contoured 2D images based on the distance transformation of the grayscale original images (CTvox; version 3.3.0). The CT Analyzer (version 1.18.8.0) software was used

for 3D and 2D analysis. In the region of interest (ROI), analyses of the bone's microarchitecture were performed. Quantitative analysis of percent bone volume (BV/TV), mean trabecular number (Tb.N), mean trabecular thickness (Tb.Th) and mean trabecular separation (Tb. Sp) were conducted for each sample.

Macroscopic observation

To evaluate the degree of articular cartilage destruction, images of the rabbit joint's femoral condyle and tibial plateau were captured (Nikon D7500 AF-S 18-140 mm f/3.5-5.6G ED VR camera). On a scale of 0–4, the degree of articular cartilage degeneration was rated (27). An observer who was blind to the treatment groups made macroscopic observations.

10.3389/fvets.2022.1034623

Histological analysis

The tibias was dissected from each group and preserved in 10% buffered formalin for 72 h, followed by 3 weeks of decalcification in a 0.5 M EDTA solution. Subsequently, sagittal sections of 5 m thickness were obtained from each joint and immersed in paraffin. Hematoxylin-eosin (H&E) staining was performed. The degree of pathological damage to knee cartilage was assessed using the Osteoarthritis Research Society International (OARSI) score (28), with higher scores indicating higher severity of cartilage degeneration. Two seasoned observers who were blind to the treatment stained all of the sections in one batch and scored them.

Immunohistochemistry

Antigen retrieval was performed on deparaffinized sections using the Target Retrieval Solution (Dako, USA). After quenching in Dako REALTM Peroxidase Blocking Solution (Dako, USA), the slides were incubated with primary antibodies against Nrf2 (Affinity, China), HO-1 (Affinity, China), MMP-3 (Proteintech, China), and MMP-13 (Proteintech, China) overnight at 4°C. Following three PBS washes, the sections were incubated with the corresponding secondary antibody for 50 min followed by an examination on the liquid diaminobenzidine (DAB) + substrate-chromogen system. Leica photomicroscope (Leica, Germany) was used to capture the images.

Western blot analysis

Western blot analysis was conducted as described previously (29). Rabbit knee joints' cartilage tissue samples from each group were dissected, homogenized, and the tissue homogenates were immediately centrifuged twice at 12,000 \times g for 15 min at 4°C to isolate supernatant for subsequent western blot analysis. The total protein extracted was quantified using the bicinchoninic acid protein assay kit (BCA kit, Thermofisher, USA). Equal proportions of proteins were transferred to polyvinylidene fluoride (PVDF) membranes following separation by 10% SDS-PAGE (Beyotime, China). The membrane was blocked in 5% bovine serum albumin (BSA, Sigma, USA) followed by incubation with primary antibodies against Nrf2, HO-1, MMP-3, and GAPDH (Affinity, China) overnight at 4°C. The next day, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (goat anti-rabbit/antimouse IgG, Affinity, China) for 1 h at room temperature. Western blotting analysis was performed by visualization of bands using the ECL chemiluminescence reagent (Vazyme, China). Using the Tannon automated gel image analysis technology (Shanghai, China), protein bands were detected. To examine the relative expressions of proteins, the Image J software was utilized.

Quantitative real-time PCR (qRT-PCR)

Total RNA was extracted from the cartilage tissue of the knee joint using the TRIzol (Invitrogen, USA). RNA was reverse transcribed into cDNA using a cDNA synthesis kit (Vazyme, China) following the manufacturer's instructions. Gene expression was quantified using the ChamQ Universal SYBR qPCR Master Mix (Vazyme, China). The primer sequences used in this study are listed in Table 1. Expression was evaluated in triplicate for each gene to reduce the processing error. Using the $2^{-\Delta\Delta Ct}$ method, relative gene expressions were evaluated by normalizing the levels of target gene to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Enzyme-linked immunosorbent assay (ELISA)

After 8 weeks of administration, blood samples were collected from rabbits in each group, and ELISA was performed to detect the levels of OA biomarkers, CTX-II and COMP, and inflammatory factors, IL-1 and TNFa, in rabbit serum. Commercially available ELISA kits were purchased from Shanghai Enzyme-linked Biotechnology Co., Ltd. The ELISA kit reagents were equilibrated at room temperature for 30 min before the test, and the serum loading time was kept under control within 5 min. The manufacturer's instructions were properly followed. For each set of samples, three replicate wells were utilized, and the OD values were calculated. The standard curve regression equation was computed using the ELISA Calc program. To calculate the relevant concentration, the model was fitted to a fourparameter logistic curve. All analyses were performed by the Heilongjiang Key Laboratory of Animals Disease Pathogenesis and Comparative Medicine.

Statistical analysis

Statistical analyses were performed using the SPSS software (version 19.0 for Windows, SPSS, Chicago, IL, USA). The results are summarized as mean \pm standard deviation (SD). For two-group comparisons, data were analyzed by a two-tailed Student's *t*-test. For multiple group comparisons, ANOVA was performed followed by the least significant difference (LSD) test for significance. *p*-value < 0.05 was considered statistically significant.

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
Nrf2	TTAGTGCTTTTGAGGATTCTTTCGG	AATTCTGTGCTTTCAGGGTGGTTCT
HO-1	CAGGTGACTGCCGAGGGTTTTA	GGAAGTAGAGCGGGGCGTAG
MMP-3	ATGGACCTTCTTCAGCAA	TCATTATGTCAGCCTCTC
MMP-13	AGGAGCATGGCGACTTCTAC	TAAAAACAGCTCCGCATCAA
GAPDH	ACTGGCGTCTTCACCACCAT	AAG GCCATGCCAGTGAGCTT

TABLE 1 The primer sequences used in qRT-PCR assay

Results

X-ray examination

Figure 2A shows a representative X-ray image of the rabbit knee joint. The articular surfaces of the femoral condyle and tibial plateau display smooth and tidy dense shadows with smooth and clear outlines. There were no significant changes in the joint space in the control group. The shadow area of the joint soft tissue was larger in the OA group, the articular surface was uneven and rough, the joint space was smaller, and osteophytes were present. The osteophytes and edema in the knee joint vanished in the Cel group, but remained narrow with a rough surface. The femoral condyle and tibial plateau of the rabbits in the BB-L and BB-H groups treated with bilobalide showed smoother articular surfaces, and the joint space improved drastically as compared to the OA group. The KL scores of the OA, Cel, BB-L, and BB-H groups were considerably higher than those of the control group (control vs. OA, Cel, BB-L p < 0.0001; control vs. BB-H p =0.0400), as shown in Figure 2B. Relative to the OA group, the KL classification scores of the BB-L and BB-H groups were considerably lower (OA vs. BB-L p = 0.0026; OA vs. BB-H p <0.0001) (Figure 2B).

Micro-CT examination

A 3D rendering of the proximal tibia is shown in Figure 3A. As shown in Figure 3B, the OA, Cel, and BB (80 mg/kg of bilobalide was administered to treat OA in rabbits) groups showed substantial reductions in BV/TV (p < 0.0001), Tb.Th (control vs. OA, Cel p < 0.0001; control vs. BB p = 0.0003), and Tb.N relative to the control group (control vs. OA p < 0.0001; control vs. Cel p = 0.0081; control vs. BB p = 0.0006). The OA (p < 0.0001), Cel (p < 0.0001), and BB groups (p = 0.0121) exhibited greater Tb.Sp values than the control group. The BV/TV (p = 0.0018), Tb.Th (p = 0.0090), and Tb.N (p = 0.0483) values in the BB group were substantially higher than those in the OA group, although the Tb.Sp value of the BB group was lower than that of the OA group (p < 0.0001).

Macro observations

After administering bilobalide treatment for 8 weeks, the tibial plateaus and femoral condyles of rabbits were observed macroscopically as showed in Figure 4A. In the control group, the cartilage surface was smooth and the edges were smooth and shiny. The degree of ulceration on the articular surface of the rabbits in the OA group was aggravated; the cartilage surface was damaged (rectangular box); the surface was dark red and tarnished; cartilage was eroded (arrow); the tibial edge was severely worn out, and the subchondral bone was exposed (rectangular box). The cartilage surface of the Cel group was slightly rough and thin. The surface of the femoral condyle was partially sunken (rectangular box), and the tibial surface was ulcerated (arrow). The cartilage surface of the BB-L group was rough and dull; the cartilage layer was thinned, and the cartilage surfaces of the femur and tibia were slightly rough (rectangular box). In the BB-H group, the articular cartilage was intact, and the cartilage surfaces of the femur and cartilage were slightly rough (arrows), but the tibial cartilage surface regained its luster, and the cartilage was intact on the whole. The score of macroscopic observation for cartilage was significantly higher in the OA group as compared to the control group (p < 0.0001). The macroscopic scores of cartilage in the BB-L and BB-H groups were significantly lower than that in the OA group (OA vs. BB-L p = 0.0226; OA vs. BB-H p < 0.0001) (Figure 4B).

Bilobalide improves histopathological changes in the knee

Figure 5 shows the HE-stained images (Figure 5A) and OARSI scores (Figure 5B) of rabbit knee tibias for each group. In the control group, the superficial, transition, radial, and calcified layers were placed in a columnar pattern from top to bottom correspondingly, and the chondrocytes were arranged in an orderly manner. The cartilage was significantly harmed; the articular cartilage's surface was rough; the matrix's staining intensity was diminished; apparent fissures were visible, there were fewer chondrocytes, and these were disorganized and aggregated in the OA group. The cartilage surface was rough; the surface chondrocytes were disorganized, and a few inflammatory



cells had entered the cartilage layer in the Cel group. The cartilage surface of the BB-L group was rough, with an irregular arrangement of surface chondrocytes, along with hypertrophy vacuolization. In the BB-H group, the cartilage's form improved gradually; the surface chondrocytes were arranged in an orderly fashion; the surface was slightly rough but the cartilage as a whole was intact. Compared to the OA group, the Cel, BB-L and BB-H groups had significantly lower OARSI scores (OA vs. Cel p = 0.0226; OA vs. BB-L p = 0.0002; OA vs. BB-H p < 0.0001).

Bilobalide up-regulates the Nrf2/HO-1 pathway in cartilage and inhibits cartilage degeneration in rabbits

Figures 6A,B shows the images of immunohistochemical staining and the percentage of positively stained cells for Nrf2,

HO-1, MMP-3, and MMP-13 in rabbit knee joint tissues of each group. The control group showed fewer positively-stained cells for MMP-3 and MMP-13, while the expressions of Nrf2 and HO-1 were higher in articular cartilage. As compared to the control group, the proportion of cells stained positively for MMP-3 and MMP-13 in the OA group was significantly high (p < 0.0001). The proportion of cells in the BB-L and BB-H groups stained positively for MMP-3 (p < 0.0001) and MMP-13 (p < 0.0001) was significantly lower than those in the OA group. Compared with the OA group, the protein expressions of Nrf2 (p = 0.0326) and OH-1 (p = 0.0335) in the BB-L group were significantly increased, and the protein expressions of Nrf2 (p = 0.0134) and OH-1 (p = 0.0278) in the BB-H group were also significantly increased. Protein and mRNA levels of Nrf2, HO-1, MMP-3, and MMP-13 in rabbit cartilage were assessed by western blotting (Figure 6C) and qRT-PCR (Figures 6D,E), respectively. Compared with the OA group, the expressions of Nrf2 (p < 0.0001) and HO-1 (OA vs. BB-L p = 0.002; OA vs.



BB-M p < 0.0001) in the BB-L group and the BB-M group were significantly increased, while the protein expressions of MMP-3 (p < 0.0001) and MMP-13 (OA vs. BB-L p = 0.0001; OA vs. BB-H p < 0.0001) were significantly decreased. Similarly, the mRNA expressions of Nrf2 (OA vs. BB-L p = 0.0020; OA vs. BB-H p < 0.0001) and HO-1 (OA vs. BB-L p = 0.0020; OA vs. BB-H p < 0.0001) and HO-1 (OA vs. BB-L p = 0.0020; OA vs. BB-H p < 0.0001) were significantly increased in the BB-L and BB-H groups, while the mRNA expressions of MMP-3 (p < 0.0001) and MMP-13 (OA vs. BB-L p = 0.0002; OA vs. BB-H p < 0.0001) were significantly decreased, which was consistent with the immunohistochemical results. Thus, bilobalide could prevent the breakdown of cartilage by reducing the levels of MMP-3 and MMP-13 by activating the Nrf2/HO-1 pathway.

Bilobalide inhibits the expression of cartilage biomarkers and inflammatory factors in the sera of OA rabbits

According to the results of ELISA (Figure 7), the levels of CTX-II (p < 0.0001), COMP(p < 0.0001), IL-1 (p < 0.0001)

0.0001), and TNF- α (p = 0.0001) in the sera from rabbits in the OA group were significantly higher than those in the control group (P < 0.05), whereas the levels of BB-L (CTX-II: p = 0.0021; COMP: p < 0.0001; IL-1: p = 0.0018; TNF- α : p = 0.0033) and BB-H (CTX-II: p < 0.0001; COMP: p < 0.0001; IL-1: p < 0.0001; TNF- α : p = 0.0001) in the Cel group (CTX-II: p = 0.0233; COMP: p = 0.0060; IL-1: p = 0.0316; TNF- α : ns), were significantly lower than those in the OA group, demonstrating that bilobalide could reverse OA-induced elevation of CTX-II, COMP, IL-1, and TNF- α levels.

Discussion

OA is caused by an imbalance in the synthesis and breakdown of articular cartilage and is a key factor for disability (30). At present, its pathogenesis is unclear but, involves changes in the microenvironment of the entire joint tissue (31). Natural products with cartilage repair, anti-inflammatory, and antioxidant properties are also widely used to prevent or treat OA (32, 33). In this study, we found that bilobalide inhibited



the protein levels of papain-induced MMP-3 and MMP-13 in rabbit cartilage tissue and the expressions of IL-1, TNF- α , CTX-II and COMP in sera by up-regulating the Nrf2/HO-1 pathway in the cartilage. Bilobalide also inhibited the destruction of the 3D structure of the trabecular bone and alleviated bone erosion, thereby preventing the pathological processes of OA in rabbits.

Animal models of OA are used to precisely duplicate the extent and progression of joint destruction, thus allowing researchers to pinpoint the underlying causes of symptoms, and the course of the illness, and explore potential therapeutic targets (34, 35). The rabbit OA model has been widely used to assess the efficacy of various compounds, and it allows the study of the underlying mechanisms in ways not possible in humans (36, 37). In order to observe the effect of bilobalide on early OA, we selected 3-month-old rabbits whose cartilage was in the growth phase. In the papaininduced OA model, for more than 2 weeks, the articular cartilage suffered minor damages only but its pathology changed considerably, and the low level of inflammation was consistent with the early pathological changes. Therefore, we administered bilobalide for 2 weeks after modeling. The protective effects on early OA were evaluated by observing the rabbits gavaged with bilobalide for 8 weeks. The rabbit OA model used in this study is a good translational model for the initial screening of compounds to evaluate disease mechanisms or treatments. Bilobalide could suppress pathological damage and degeneration of cartilage and markedly reduce the expression of the matrix degradation proteins, MMP-3 and MMP-13, suggestive of its protective effects against cartilage destruction. Notably, we assessed the effects of bilobalide on bone remodeling in a rabbit model of OA to assess its preventive activity on various physiological features of OA.

An imbalance between cartilage degradation and repair mechanisms is the primary cause of the early-onset OA (35, 38). However, some studies indicate that synovitis and subchondral bone remodeling may occur before the joint deterioration in the early phases of OA (39). Due to enhanced bone remodeling, OA is linked to early bone loss, sluggish turnover, densification of the subchondral plate, and total cartilage loss (40). Osteoclast bone resorption and osteoblastic bone production are coupled during bone remodeling, replacing the damaged bone with a new bone (41). As compared to the control group, the percentage bone volume (BV/TV), mean trabecular number (Tb.N) and mean trabecular thickness



(Tb.Th) of the OA group decreased significantly, and the mean trabecular separation (Tb.Sp) increased. This may be because bone catabolism is greater than its anabolism in the early stage of OA, and the subchondral bone mass decreases. The increase in Tb.Sp parameter indicated an increase in the average width of the medullary cavity between trabecular bone, suggesting that bone resorption was activated in the subchondral bone microenvironment. After bilobalide intervention, as compared to the OA group, BV/TV, Tb.N and Tb.Th increased significantly, while Tb.Sp decreased substantially, indicating that bilobalide could delay the process of bone resorption and inhibit the destruction of the 3D structure of trabecular bone.

Increased oxidative stress and age-related changes in mitochondrial antioxidant capacity may cause abnormalities in physiological cell signaling that jeopardize cellular integrity and accelerate aging (42, 43). The function of Nrf2 transcription factors in cartilage homeostasis and aging has attracted more attention recently (14, 44). A significant downstream target of Nrf2, HO-1 is essential for maintaining the redox balance in cartilage (45). *Ginkgo biloba* L. extract exerts antioxidant effects against several disorders (46–48). Western blotting showed that the expressions of HO-1 and Nrf2 increased markedly in the papain-induced OA model, indicating that the Nrf2/HO-1 pathway was affected by oxidative stress. It was activated but insufficiently resistant to the occurrence

of cartilage damage. Different doses of bilobalide could not only alleviate the pathological changes in the OA model but the expressions of Nrf2 and HO-1 in the BB-L and BB-H groups increased further and showed better performance than in the Cel group. MMP-13 and MMP-3 are major proteases involved in the degradation of the extracellular matrix of cartilage (49). It has the special ability to cleave type II collagen or non-collagen (50, 51). As compared to the OA group, MMP-3 and MMP-13 decreased significantly after gavage for 8 weeks. We hypothesized that bilobalide's specific modulation of the Nrf2/HO-1 pathway was responsible for the decline in the levels of matrix degradation protein. This implied that bilobalide prevented matrix breakdown by stimulating the Nrf2/HO-1 axis, which in turn suppressed oxidative stress in the cartilage.

OA biomarkers have been widely used to diagnose OA, measure the extent of pathological progression, and assess the effectiveness of drugs (52, 53). Studies have shown that the type II collagen metabolites, CTX-II, and the non-collagen metabolite, COMP, in the extracellular matrix can be used to assess the extent of cartilage damage (54). The levels of CTX-II and COMP in the OA group increased significantly after modeling as compared to the control group, indicating that during cartilage degeneration, the breakdown of extracellular matrix was accelerated and CTX-II and COMP entered the blood, resulting in disorders of cartilage metabolism.



Bilobalide inhibits the production of matrix degrading proteins MMP-3 and MMP-13, *via* Nrf2/HO-1. (A) Representative images of immunohistochemical staining for Nrf2, HO-1, MMP-3 (200 ×), and MMP-13 proteins in rabbit cartilage in each group. (B) Percentage of positive cells after eight weeks of treatment. (C) Assessment and quantification of Nrf2, HO-1, MMP-3, and MMP-13 protein levels in cartilage by western blotting. (D,E) The expression of Nrf2, HO-1, MMP-3, and MMP-13 mRNA in rabbit cartilage tissue by qRT-PCR. All data are presented as mean \pm SD (n = 3). * p < 0.05 and ** p < 0.01 vs. control group; # p < 0.05 and ## p < 0.01 vs. OA group.



Previous studies have shown that treatment with 10 mg/kg glycyrrhizin significantly inhibited the levels of CTX-II in OA rats (55). Rats without ovaries expressed less CTX-II and COMP in their sera for 9 weeks when administered 51 mg/kg of soybean isoflavones (56). Treatment for 7 days with 4 mg/kg undenatured type II collagen in an intragastrically administered of iodoacetic acid-induced rat OA model, resulted in an effective reduction in the expression of COMP in the serum (1). After administration of bilobalide, the levels of CTX-II, COMP, IL-1, and TNF- α in rabbit sera reduced significantly, indicating that bilobalide could inhibit the degradation of extracellular matrix and exert chondroprotection through anti-inflammatory and anti-extracellular matrix degradation effects.

Bilobalide exerted antioxidant and anti-matrix degradation effects by activating the Nrf2/HO-1 pathway in the cartilage, thereby inhibiting and improving cartilage degeneration in rabbits. It could also repair papain-induced cartilage loss and subchondral bone injury in rabbits with OA. In the early stages of OA, bilobalide improved the biomechanical characteristics and microstructural alterations of the subchondral bone. However, only *in vivo* tests were conducted in this study to assess the anti-OA impact of bilobalide. Further, *in vitro* research is therefore required to clarify the molecular mechanism underlying bilobalide's effects on subchondral bone remodeling. Rigorous toxicity tests and pharmacological experiments are, required to ascertain the long-term effectiveness of bilobalide in the treatment of OA. Nevertheless, the protective mechanism of bilobalide on articular cartilage may be better understood as a result of our observations.

Data availability statement

The original contributions presented in the study are included the article/supplementary in material, further inquiries be directed to can the corresponding author/s.

Ethics statement

The animal study was reviewed and approved by Laboratory Animal Welfare and Ethics Committee of Northeast Agricultural University (#NEAU-2022-01-0025-1).

Author contributions

TM, HC, and LG conceived and designed the experiments. HR, LL, JZhao, YY, and LJ performed the experiments. TM, HR, XL, YZ, and XX analyzed the data and prepared figures. TM, HC, and JZhang wrote the manuscript. All the authors read and approved the final manuscript.

Funding

This work was supported by Inner Mongolia Autonomous Region Science and Technology Project (2022YFSH0052), Xinjiang Uygur Autonomous Region Science and Technology Support Project Plan (2020E0236), Applied Technology Research and Development Plan of Heilongjiang (GA18B203), and National Science and Technology Major Projects and Key R&D Projects Provincial-level Funded Projects (GX18B023).

Acknowledgments

Thanks to Wuhan Servicebio Technology Co., Ltd. for the technical support of the pathological section of this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Orhan C, Juturu V, Sahin E, Tuzcu M, Ozercan IH, Durmus AS, et al. Undenatured type II collagen ameliorates inflammatory responses and articular cartilage damage in the rat model of osteoarthritis. *Front Vet Sci.* (2021) 8:617789. doi: 10.3389/fvets.2021.617789

2. Sifre V, Soler C, Segarra S, Redondo JI, Domenech L, Ten-Esteve A, et al. Improved joint health following oral administration of glycosaminoglycans with native type ii collagen in a rabbit model of osteoarthritis. *Animals (Basel).* (2022) 12. doi: 10.3390/ani12111401

3. Michael JW, Schluter-Brust KU, Eysel P. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee. *Dtsch Arztebl Int.* (2010) 107:152-62. doi: 10.3238/arztebl.2010.0152

4. Cooper C, Chapurlat R, Al-Daghri N, Herrero-Beaumont G, Bruyere O, Rannou F, et al. Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say? *Drugs Aging.* (2019) 36:15– 24. doi: 10.1007/s40266-019-00660-1

5. Lu J, Xie L, Liu K, Zhang X, Wang X, Dai X, et al. Bilobalide: a review of its pharmacology, pharmacokinetics, toxicity, and safety. *Phytother Res.* (2021) 35:6114–30. doi: 10.1002/ptr.7220

6. Zhang H, Cao N, Yang Z, Fang X, Yang X, Li H, et al. Bilobalide alleviated dextran sulfate sodium-induced experimental colitis by inhibiting m1 macrophage polarization through the nf-kappab signaling pathway. *Front Pharmacol.* (2020) 11:718. doi: 10.3389/fphar.2020.00718

7. Shi C, Wu F, Yew DT, Xu J, Zhu Y. Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. *Apoptosis.* (2010) 15:715–27. doi: 10.1007/s10495-010-0492-x

8. Liu Q, Jin Z, Xu Z, Yang H, Li L, Li G, et al. Antioxidant effects of ginkgolides and bilobalide against cerebral ischemia injury by activating the Akt/Nrf2 pathway in vitro and in vivo. *Cell Stress Chaperones.* (2019) 24:441–52. doi: 10.1007/s12192-019-00977-1

9. Defeudis FV. Bilobalide and neuroprotection. *Pharmacol Res.* (2002) 46:565-8. doi: 10.1016/S1043-6618(02)00233-5

10. Stromgaard K, Nakanishi K. Chemistry and biology of terpene trilactones from Ginkgo biloba. *Angew Chem Int Ed Engl.* (2004) 43:1640-58. doi: 10.1002/anie.200300601

11. Ma T, Lv L, Yu Y, Jia L, Song X, Xu X, et al. Bilobalide exerts antiinflammatory effects on chondrocytes through the AMPK/SIRT1/mTOR pathway to attenuate ACLT-induced post-traumatic osteoarthritis in rats. *Front Pharmacol.* (2022) 13:783506. doi: 10.3389/fphar.2022.783506

12. Mao D, Li H, Zhang L, Xu J, Yu C, Zhang Q, et al. Bilobalide alleviates IL-17-induced inflammatory injury in ATDC5 cells by downregulation of microRNA-125a. *J Biochem Mol Toxicol.* (2019) 33:e22405. doi: 10.1002/jbt.22405

13. Lepetsos P, Papavassiliou AG. ROS/oxidative stress signaling in osteoarthritis. Biochim Biophys Acta. (2016) 1862:576–91. doi: 10.1016/j.bbadis.2016.01.003 14. Marchev AS, Dimitrova PA, Burns AJ, Kostov RV, Dinkova-Kostova AT, Georgiev MI, et al. Oxidative stress and chronic inflammation in osteoarthritis: can NRF2 counteract these partners in crime? *Ann N Y Acad Sci.* (2017) 1401:114–35. doi: 10.1111/nyas.13407

15. Zahan OM, Serban O, Gherman C, Fodor D. The evaluation of oxidative stress in osteoarthritis. *Med Pharm Rep.* (2020) 93:12–22. doi: 10.15386/mpr-1422

16. Collins JA, Wood ST, Nelson KJ, Rowe MA, Carlson CS, Chubinskaya S, et al. Oxidative stress promotes peroxiredoxin hyperoxidation and attenuates pro-survival signaling in aging chondrocytes. *J Biol Chem.* (2016) 291:6641–54. doi: 10.1074/jbc.M115.693523

17. Neri S, Guidotti S, Bini C, Pelotti S, D'Adamo S, Minguzzi M, et al. Oxidative stress-induced DNA damage and repair in primary human osteoarthritis chondrocytes: focus on IKKalpha and the DNA Mismatch Repair System. *Free Radic Biol Med.* (2021) 166:212–25. doi: 10.1016/j.freeradbiomed.2021.02.020

 Zou LX, Yu L, Zhao XM, Liu J, Lu HG, Liu GW, et al. MiR-375 mediates chondrocyte metabolism and oxidative stress in osteoarthritis mouse models through the JAK2/STAT3 signaling pathway. *Cells Tissues Organs*. (2019) 208:13– 24. doi: 10.1159/000504959

19. Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. *Biochim Biophys Acta Mol Cell Res.* (2018) 1865:721–33. doi: 10.1016/j.bbamcr.2018.02.010

20. Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. *Cell Mol Life Sci.* (2016) 73:3221-47. doi:10.1007/s00018-016-2223-0

21. Suzuki T, Yamamoto M. Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med. (2015) 88:93–100. doi: 10.1016/j.freeradbiomed.2015.06.006

22. Yan Z, Qi W, Zhan J, Lin Z, Lin J, Xue X, et al. Activating Nrf2 signalling alleviates osteoarthritis development by inhibiting inflammasome activation. *J Cell Mol Med.* (2020) 24:13046–57. doi: 10.1111/jcmm.15905

23. Heinrich M, Appendino G, Efferth T, Furst R, Izzo AA, Kayser O, et al. Best practice in research—Overcoming common challenges in phytopharmacological research. *J Ethnopharmacol.* (2020) 246:112230. doi: 10.1016/j.jep.2019.112230

24. Izzo AA, Teixeira M, Alexander SPH, Cirino G, Docherty JR, George CH, et al. A practical guide for transparent reporting of research on natural products in the British Journal of Pharmacology: Reproducibility of natural product research. *Br J Pharmacol.* (2020) 177:2169–78. doi: 10.1111/bph.15054

25. Maitirouzi J, Yanna L, Abulizi A, Aihemaitiniyazi A, Kuerban S, Shaojun H, et al. Effects of Uygur sand therapy on the mechanical properties of femurs in osteoarthritic rabbits. *Biomed Mater Eng.* (2017) 28:633–42. doi: 10.3233/BME-171701

26. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. *Ann Rheum Dis.* (1957) 16:494–502. doi: 10.1136/ard.16.4.494

27. Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR, Currie MG, et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. *Arthritis Rheum.* (1998) 41:1275–86. doi: 10.1002/1529-0131(199807)41:7&dt;1275::AID-ART19>3.0.CO;2-T

28. Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, et al. Osteoarthritis cartilage histopathology: grading and staging. *Osteoarthritis Cartilage*. (2006) 14:13–29. doi: 10.1016/j.joca.2005.07.014

29. Ma TW, Wen YJ, Song XP, Hu HL, Li Y, Bai H, et al. Puerarin inhibits the development of osteoarthritis through antiinflammatory and antimatrix-degrading pathways in osteoarthritis-induced rat model. *Phytother Res.* (2020). doi: 10.1002/ptr.6988

30. Xia B, Di C, Zhang J, Hu S, Jin H, Tong P, et al. Osteoarthritis pathogenesis: a review of molecular mechanisms. *Calcif Tissue Int.* (2014) 95:495–505. doi: 10.1007/s00223-014-9917-9

31. Kumar A, Palit P, Thomas S, Gupta G, Ghosh P, Goswami RP, et al. Osteoarthritis: prognosis and emerging therapeutic approach for disease management. *Drug Dev Res.* (2021) 82:49–58. doi: 10.1002/ddr.21741

32. Mobasheri A. Intersection of inflammation and herbal medicine in the treatment of osteoarthritis. *Curr Rheumatol Rep.* (2012) 14:604–16. doi: 10.1007/s11926-012-0288-9

33. Sukhikh S, Noskova S, Ivanova S, Ulrikh E, Izgaryshev A, Babich O, et al. Chondroprotection and molecular mechanism of action of phytonutraceuticals on osteoarthritis. *Molecules*. (2021) 26. doi: 10.3390/molecules26082391

34. Cope PJ, Ourradi K, Li Y, Sharif M. Models of osteoarthritis: the good, the bad and the promising. *Osteoarthritis Cartil.* (2019) 27:230-9. doi: 10.1016/j.joca.2018.09.016

35. Gregory MH, Capito N, Kuroki K, Stoker AM, Cook JL, Sherman SL, et al. A review of translational animal models for knee osteoarthritis. *Arthritis*. (2012) 2012:764621. doi: 10.1155/2012/764621

36. Kikuchi T, Sakuta T, Yamaguchi T. Intra-articular injection of collagenase induces experimental osteoarthritis in mature rabbits. *Osteoarthritis Cartil.* (1998) 6:177–86. doi: 10.1053/joca.1998.0110

37. Muehleman C, Green J, Williams JM, Kuettner KE, Thonar EJ, Sumner DR, et al. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. *Osteoarthritis Cartil.* (2002) 10:226–33. doi: 10.1053/joca.2001.0506

38. Burr DB, Gallant MA. Bone remodelling in osteoarthritis. *Nat Rev Rheumatol.* (2012) 8:665–73. doi: 10.1038/nrrheum.2012.130

39. Hu W, Chen Y, Dou C, Dong S. Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis. *Ann Rheum Dis.* (2021) 80:413–22. doi: 10.1136/annrheumdis-2020-218089

40. Xiao ZF, Su GY, Hou Y, Chen SD, Lin DK. Cartilage degradation in osteoarthritis: a process of osteochondral remodeling resembles the endochondral ossification in growth plate? *Med Hypotheses.* (2018) 121:183-7. doi: 10.1016/j.mehy.2018.08.023

41. Hu W, Zhang L, Dong Y, Tian Z, Chen Y, Dong S, et al. Tumour dormancy in inflammatory microenvironment: a promising therapeutic

strategy for cancer-related bone metastasis. Cell Mol Life Sci. (2020) 77:5149-69. doi: 10.1007/s00018-020-03572-1

42. Bolduc JA, Collins JA, Loeser RF. Reactive oxygen species, aging and articular cartilage homeostasis. *Free Radic Biol Med.* (2019) 132:73– 82. doi: 10.1016/j.freeradbiomed.2018.08.038

43. McCulloch K, Litherland GJ, Rai TS. Cellular senescence in osteoarthritis pathology. *Aging Cell*. (2017) 16:210–8. doi: 10.1111/acel.12562

44. Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, et al. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. *Free Radic Biol Med.* (2015) 88:108–46. doi: 10.1016/j.freeradbiomed.2015.06.021

45. Takada T, Miyaki S, Ishitobi H, Hirai Y, Nakasa T, Igarashi K, et al. Bach1 deficiency reduces severity of osteoarthritis through upregulation of heme oxygenase-1. *Arthritis Res Ther.* (2015) 17:285. doi: 10.1186/s13075-015-0792-1

46. Eckert A, Keil U, Kressmann S, Schindowski K, Leutner S, Leutz S, et al. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. *Pharmacopsychiatry*. (2003) 36 Suppl 1:S15–23. doi: 10.1055/s-2003-40449

47. Wang C, Wang B. Ginkgo biloba extract attenuates oxidative stress and apoptosis in mouse cochlear neural stem cells. *Phytother Res.* (2016) 30:774–80. doi: 10.1002/ptr.5572

48. Zhang S, Yi X, Su X, Jian Z, Cui T, Guo S, et al. Ginkgo biloba extract protects human melanocytes from H2 O2 -induced oxidative stress by activating Nrf2. *J Cell Mol Med.* (2019) 23:5193–9. doi: 10.1111/jcmm.14393

49. Mehana EE, Khafaga AF, El-Blehi SS. The role of matrix metalloproteinases in osteoarthritis pathogenesis: An updated review. *Life Sci.* (2019) 234:116786. doi: 10.1016/j.lfs.2019.116786

50. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. *Front Biosci.* (2006) 11:529–43. doi: 10.2741/1817

51. Hu Q, Ecker M. Overview of MMP-13 as a promising target for the treatment of osteoarthritis. *Int J Mol Sci.* (2021) 22. doi: 10.3390/ijms22041742

52. Kumavat R, Kumar V, Malhotra R, Pandit H, Jones E, Ponchel F, et al. Biomarkers of joint damage in osteoarthritis: current status and future directions. *Mediators Inflamm.* (2021) 2021:5574582. doi: 10.1155/2021/5574582

53. Watt FE. Osteoarthritis biomarkers: year in review. Osteoarthritis Cartil. (2018) 26:312-8. doi: 10.1016/j.joca.2017.10.016

54. Bai B, Li Y. Combined detection of serum CTX-II and COMP concentrations in osteoarthritis model rabbits: an effective technique for early diagnosis and estimation of disease severity. *J Orthop Surg Res.* (2016) 11:149. doi: 10.1186/s13018-016-0483-x

55. Luo Y, Li J, Wang B, Zhang Q, Bian Y, Wang R, et al. Protective effect of glycyrrhizin on osteoarthritis cartilage degeneration and inflammation response in a rat model. *J Bioenerg Biomembr.* (2021) 53:285–93. doi: 10.1007/s10863-021-09889-1

56. Toda T, Sugioka Y, Koike T. Soybean isoflavone can protect against osteoarthritis in ovariectomized rats. *J Food Sci Technol.* (2020) 57:3409–14. doi: 10.1007/s13197-020-04374-w